Ruchit Patel

Representative Strategic Company Experience

• Becton Dickinson on its $4.2 billion acquisition of Edwards Lifesciences' Critical Care business
  
• National Amusements in the proposed sale of control of Paramount Global to affiliates of Skydance Media for $2.4 billion
• Nippon Steel Corporation on its ~$14 billion bid for US Steel
• Immunogen on the antitrust aspects of its sale to AbbVie valued ~$10.1 billion
• AbbVie in its acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease
• Bloomberg on antitrust aspects of its planned acquisition of Broadway Technology, a cutting-edge provider of high-performance front-office fintech solutions
• Pfizer Inc. on several transactions, including Biohaven (~$12 billion), Global Blood Therapeutics (~$5.4 billion), Trillium Therapeutics Inc. ($2.26 billion), Medivation ($14 billion) and others
• Medtronic on several transactions, including Covidien ($43 billion), Mazor Robotics ($1.64 billion), Affera (~$1 billion), Intersect ($1.1 billion) and others
• Google on its acquisition of an interest in Reliance Jio Platforms valued at $4.5 billion
• Acceleron Pharma on its approximately $11.5 billion sale to Merck
• Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
• Takeda Pharmaceutical Company Limited in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
• Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion
• Blue Coat on the European aspects of its sale to Symantec valued at over US$4 billion
• Biomet, the divestiture buyer, on J&J’s US$21.3 billion acquisition of Synthes
• Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
• Abbott on its US$4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase I

Representative Private Equity Experience

• Bain Capital on its $5.6 billion acquisition of PowerSchool Holdings, Inc.
• Bain Capital on its $4.5 billion acquisition of Envestnet
• Advent on its investment in Prometheus Group
• Advent on its $4.25 billion acquisition of Baxter BioPharma Solutions
• TPG on its $4 billion sale of McAfee Enterprise to STG
• TPG on its $14 billion sale of McAfee Consumer to Advent International and Permira
• TPG on its $4 billion sale of Wind River to Aptiv
• Bain Capital on its US$18 billion acquisition of Toshiba Memory Corporation from Toshiba Corporation, by way of a Bain Capital-led consortium including Apple, Seagate Technology, Kingston Technology, Hoya, Dell Technologies and SK Hynix
• Baring Private Equity Asia on its ~$7 billion merger with EQT
• Bain Capital on its $8.5 billion acquisition of Hitachi Metals
• Advent International on its $2.7 billion acquisition of Nielsen IQ
• Warburg Pincus and General Atlantic on their $2 billion acquisition of Santander Asset Management

Investigations

• Google with several multi-jurisdictional competition law investigations
• The Coca-Cola Company in several transactions and in defence of its commercialization practices
• SK Hynix on settlement negotiations with the European Commission in DRAM
• IBM with a complaint to the European Commission in relation to “midrange” servers
• Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
• Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/ Alliance Unichem in the Competition Appeal Tribunal
• An intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matter